EXECUTIVE SUMMARY - GOLD

More documents

Recommendations

Info

pulmonary disease. Respir Care Clin N Am 1998;4(3):425-38. 263. Peach H, Pathy MS. Follow-up study of disability among elderly patients discharged from hospital with exacerbations of chronic bronchitis. Thorax 1981;36(8):585-9. 264. Eaton T, Withy S, Garrett JE, Mercer J, Whitlock RM, Rea HH. Spirometry in primary care practice: the importance of quality assurance and the impact of spirometry workshops. Chest 1999;116(2):416-23. 265. Schermer TR, Jacobs JE, Chavannes NH, Hartman J, Folgering HT, Bottema BJ, et al. Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD). Thorax 2003;58(10):861-6. 266. Schermer T, Eaton T, Pauwels R, van Weel C. Spirometry in primary care: is it good enough to face demands like World COPD Day Eur Respir J 2003;22(5):725-7. 267. Rea H, McAuley S, Stewart A, Lamont C, Roseman P, Didsbury P. A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease. Intern Med J 2004;34(11):608-14. 268. Kessler R, Stahl E, Vogelmeier C, Haughney J, Trudeau E, Lofdahl CG, Partridge MR. Patient understanding, detection, and experience of COPD exacerbations: an observational, interviewbased study. Chest 2006 Jul;130(1):133-42. 269. Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 2006 Aug;130(2):334-42. 270. Zhou Y, Wang X, Zeng X, Qiu R, Xie J, Liu S, Zheng J, Zhong N, Ran P. Positive benefits of theophylline in a randomised, double-blind, parallel-group, placebocontrolled study of low-dose, slowrelease theophylline in the treatment of COPD for 1 year. Respirology 2006 Sep;11(5):603- 10. 271. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007 Feb 22;356(8):775-89. 272. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007 Jan 15;175(2):144-9. 273. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker- Herceg R, Barnathan ES, Murray J; COPD Investigators. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007 May 1;175(9):926-34. 274. Guo R, Pittler MH, Ernst E. Herbal medicines for the treatment of COPD: a systematic review. Eur Respir J 2006 Aug;28(2):330-8.
275. Price LC, Lowe D, Hosker HS, Anstey K, Pearson MG,Roberts CM; British Thoracic Society and the Royal College of Physicians Clinical Effectiveness Evaluation Unit (CEEu). UK National COPD Audit 2003: Impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation. Thorax 2006 Oct;61(10):837-42. 276. Wood-Baker R, McGlone S, Venn A, Walters EH. Written action plans in chronic obstructive pulmonary disease increase appropriate treatment for acute exacerbations. Respirology 2006 Sep;11(5):619-26.
Page 1 and 2:
EXECUTIVE SUMMARY Aggiornamento 200
Page 3 and 4:
EXECUTIVE SUMMARY PROGETTO MONDIALE
Page 5 and 6:
Metodologia Dopo la pubblicazione d
Page 7 and 8:
Contesto delle Cure Primarie, pone
Page 9 and 10: Tuttavia, poiché l’invecchiament
Page 11 and 12: dell’aumento dell’età media de
Page 13 and 14: BPCO (32, 33). Non tutti i fumatori
Page 15 and 16: • Tutti i pazienti con VEMS < 50%
Page 17 and 18: Ulteriori indagini Per soggetti in
Page 19 and 20: Monitoraggio delle comorbidità Si
Page 21 and 22: concetto di esposizione individuale
Page 23 and 24: diretti a migliorare la qualità di
Page 25 and 26: Le relazioni dose-risposta, studiat
Page 27 and 28: Antibiotici. L’uso preventivo con
Page 29 and 30: Essa è generalmente somministrata
Page 31 and 32: ichiedere un cambiamento nella tera
Page 33 and 34: informazioni cliniche, identificano
Page 35 and 36: itenzione di CO2 o acidosi. La masc
Page 37 and 38: I rischi maggiori sono la polmonite
Page 39 and 40: l’esposizione ai fattori di risch
Page 41 and 42: implementazione di un sistema sanit
Page 43 and 44: 29. Blanco I, de Serres FJ, Fernand
Page 45 and 46: preventing chronic obstructive pulm
Page 47 and 48: 86. Ackermann-Liebrich U, Leuenberg
Page 49 and 50: 114. Gross N, Tashkin D, Miller R,
Page 51 and 52: The Netherlands. J Epidemiol Commun
Page 53 and 54: 166. Jennings AL, Davies AN, Higgin
Page 55 and 56: COPD: a summary of the ATS/ERS posi
Page 57 and 58: pulmonary disease. Department of Ve
Page 59: 249. Esteban A, Anzueto A, Alia I,
show all

EXECUTIVE SUMMARY - GOLD

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?